Botulinum toxin may offer a practical new option for patients with painful, treatment‑resistant ischemic lesions of the fingers, according to a systematic review and individual‑patient meta‑analysis published in JAMA Dermatology by investigators at the McGill University Health Centre (MUHC) in Montreal. Researchers at the Research Institute of the MUHC report that injections of botulinum toxin were associated with complete healing of digital lesions in more than 85% of 119 p

There are no associations between AD and cardiovascular risk factors in children and adolescents.

Photo by Benis Arapovic via Vecteezy Researchers in Arkansas are developing experimental surgical sutures that slowly release anti-inflammatory drugs at the wound site, aiming to curb local inflammation, reduce scarring, and potentially improve outcomes of delicate procedures. Working in the laboratory of chemist Sharon K. Hamilton, PhD, at Ouachita Baptist University, undergraduate researcher Mieya Kirby has focused on electrospun polymers, which can be drawn under high volt

Mastocytosis. Photo by Doc James via Wikimedia Commons Recent findings show treatment with the selective KIT D816V inhibitor avapritinib for indolent systemic mastocytosis (ISM) improved dermatologic symptoms, decreased skin lesion size, normalized skin lesion colour, and reduced skin mast cell burden. The study was published in the Journal of the American Academy of Dermatology . In a press release , the study’s senior author, Karin Hartmann, MD, said that her mastocytosis p

Upadacitinib was significantly effective in treating AD and modestly effective in treating HS

MFSD2A is required for the uptake of LPCs containing linoleic acid (LPC18:2) from the blood for normal development of the epidermis. The absence of MFSD2A leads to increased skin inflammation and thickening of the epidermis. Photo by: Bernice Wong Researchers at Duke-NUS Medical School in Singapore have pinpointed a lipid transporter that enables epidermal cells to import key fatty acids from the bloodstream, a mechanism they say is critical for preserving skin barrier integr

Squamous cell carcinoma in situ. Photo by Klaus D. Peter via Wikimedia Commons Findings from a preclinical study show a topical cream that blocks the immune-suppressing enzyme LSD1 suppressed tumour growth in two models of cutaneous squamous cell carcinoma (cSCC). The study, published in the Journal of Clinical Investigation , describes how the cream, developed by researchers at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, prevents LSD1

Adjunct topical insulin alongside microneedling decreases the rate of poor improvement scores in acne patients.